2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Metabolic Syndrome
1
Lymphoma, Non-Hodgkin
1
Heart Failure
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Cardiomyopathies
1
Interventions
pembrolizumab
1262
Specimen Handling
924
Magnetic Resonance Spectroscopy
829
Carboplatin
821
Cyclophosphamide
799
Cisplatin
722
Nivolumab
667
Paclitaxel
627
Radiotherapy
608
Gemcitabine
570
Biopsy
557
Bevacizumab
478
Dexamethasone
437
fludarabine
407
Docetaxel
377
venetoclax
367
Oxaliplatin
364
Capecitabine
355
Fluorouracil
355
atezolizumab
350
durvalumab
332
Rituximab
329
Drug Therapy
325
Doxorubicin
316
Radiosurgery
314
Standard of Care
309
Blood Specimen Collection
308
Pemetrexed
304
Ipilimumab
298
Radiation
285
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pulse Wave Analysis
×
1 year
×
Clear all
NCT07041827
2025-06-27
CLARITY
The Netherlands Cancer Institute
Completed
217 enrolled